Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 8/20 | 1.00 |
| ▸ | SLC40A1 | Q9NP59 | 9/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.76 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.76 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.76 |
| ▸ | G6PD | P11413 | 1/20 | 0.76 |
| ▸ | METAP2 | P50579 | 1/20 | 0.76 |
| ▸ | METAP1 | P53582 | 1/20 | 0.76 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | MITF | O75030 | 1/20 | 0.75 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13765596 | 0.87 | GLO1 (0.78) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL442367 | 0.87 | SLC40A1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL30925415 | 0.87 | GLO1 (0.76) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL27214177 | 0.87 | GLO1 (0.76) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL15508515 | 0.86 | GLO1 (0.76) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL30925492 | 0.86 | GLO1 (0.76) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL9447001 | 0.86 | GLO1 (0.75) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL3825367 | 0.86 | TDP1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL13638616 | 0.86 | SLC40A1 (0.76) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL6981081 | 0.86 | SLC40A1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021146082-A1 | BIHETEROCYCLIC INHIBITORS OF ISPF FOR TREATMENT OF MICROBIAL INFECTIONS | POINT LOMA NAZARENE UNIVERSITY (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20140073668-A1 | N-QUINOLIN-BENZENSULFONAMIDES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS AND INFLAMMATION | THE TRUSTEES OF COLUMBIA UNVERSITY IN THE CITY OF NEW YORK (US) | 2014-03-13 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| EP-0991624-B1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-11-19 | — | — | EP | disclosed |
| EP-0991624-A1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999000371-A1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073668-A1 | N-QUINOLIN-BENZENSULFONAMIDES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS AND INFLAMMATION | NFKBIA, RELA, NFKB2 | GLO1 4231/4885SLC40A1 1494/4885TDP1 3689/4885 |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | HELZ, MMEL1, GAA | GLO1 2965/4885SLC40A1 408/4885TDP1 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.